A new framework from the U.K.’s National Health Service (NHS) has sparked some concerns as the agency continues its push to lower prescription drug prices, the Pink Sheet reports.
“It’s now clearly in the public domain, for those who didn’t know, that NHS England wants to get companies to price below the cost-effectiveness threshold,” an industry insider tells the Pink Sheet.
To read the full report, click here. (Paid subscription required)
